Rizatriptan vs Placebo for Attacks of Vestibular Migraine: A Randomized Clinical Trial

Area of Science:

• Neurology
• Neurotology

Background:

• Vestibular migraine lacks established treatments.
• Current treatment options are limited, necessitating research into effective therapies.

Purpose of the Study:

• To evaluate the efficacy of rizatriptan in treating acute vestibular migraine attacks.
• To compare rizatriptan's effectiveness against a placebo.

Main Methods:

• A double-blind, randomized clinical trial involving adults diagnosed with vestibular migraine.
• Participants received either 10 mg of rizatriptan or a placebo to treat up to three attacks.
• Primary outcomes measured symptom reduction (vertigo, unsteadiness/dizziness) at 1 hour.

Main Results:

• Rizatriptan showed no significant difference from placebo in reducing vertigo or unsteadiness/dizziness at 1 hour.
• Secondary outcomes, including complete symptom resolution and associated symptoms at 1 hour, were also not significantly improved.
• At 24 hours, rizatriptan demonstrated a medium effect over placebo for unsteadiness/dizziness and motion sensitivity, with post hoc analyses suggesting benefits for headache and photophobia/phonophobia.

Conclusions:

• Rizatriptan was found to be ineffective for treating vestibular migraine attacks at the 1-hour mark.
• The drug provided limited benefit for symptoms at 24 hours, and findings do not support its use for vestibular migraine.
• No serious adverse effects were reported, indicating a favorable safety profile.